Redefining Venous Anastomosis with EndoForce™

EndoForce image

Phraxis, Inc. is an early-stage medical device company founded to develop novel treatment solutions for patients who need vascular access to enable hemodialysis. Our first planned product for commercialization, the EndoForce™, is a transcatheter-delivered endovascular anastomotic connector that provides a unique approach for patients who need vascular access.

Invented by our CEO and interventional nephrologist, Dr. Alex Yevzlin, the EndoForce™ embodies years of clinical expertise and represents a significant leap forward in renal care solutions.

EndoForce™ provides an alternative, less traumatic, endovascular venous anastomosis for arteriovenous graft implantation addressing clinical challenges associated with a traditional sutured anastomosis.

Intuitive Deployment

The EndoForce™ is deployed within a peripheral vein using standard transcatheter methods and a customized easy to use Delivery System. Connection to the graft is made using standard endovascular techniques.

Extend Graft Patency

In the primary endpoint of the main investigational device exemption clinical trial, EndoForce™ demonstrated a 92% cumulative patency rate, surpassing the 80% rate associated with suture anastomosis.

Unique, Innovative Design

The EndoForce™ Connector is a patented implant designed for coaxial, endovascular anastomosis of a vein to an arteriovenous graft. Design features include: a flexible nitinol segment that provides a wide range of angles for implantation, a rigid segment that provides maximum radial force to secure the device within the graft, and nitinol anchoring barbs that secure the device to the vein wall.

Ari Kramer, MD headshot

Ari Kramer, MD

Vascular Surgeon and Clinical Study Investigator

Spartanburg Regional Medical Center

“I found the device to be intelligently designed, with an intuitive implantation technique which was easy to learn and employ, reduced my operating time and facilitated both excellent and durable outcomes that outstripped our standard hand-sewn anastomoses. Overall, this is an outstanding and disruptive technology that should be welcomed in the AV access space.”

Contact Us

Contact Form

"*" indicates required fields

Name*